Nuo Therapeutics, Inc. (AURX)
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Biotechnology
Nuo Therapeutics, Inc.
OTC:AURXHealthcare · Biotechnology
+0.00%$1.30
Mkt Cap$62.96M
Float20.25M
O/S48.43M
Inst Own-
SI<0.1%
Dilution
MCap$62.96M
Float20.25M
O/S48.43M
Dilution